Review of 13 Trials Says Antidepressant Edronax (Reboxetine) is Ineffective

LONDON, Oct 13 (Reuters) - Pfizer's (PFE.N) antidepressant reboxetine is an "ineffective and potentially harmful" drug and published data on it overestimates the benefits and underplays the risks, a study by German researchers said on Wednesday.